[ad_1]
The British company, “AstraZeneca”, rejected allegations that its corona vaccine was linked to blood clots that were registered in different countries by people who had received the vaccine.
The British “AstraZeneca” for pharmaceutical industries announced, this Friday, its rejection of the accusations that its vaccine against the emerging corona virus is linked to blood clots that were registered in different countries of people who had received the vaccine, according to the newspaper British “Telegraph”.
And the dangerous symptoms, which included blood clots, caused several countries in Europe and the world to discontinue the use of the AstraZeneca vaccine to review it and verify its safety.
The World Health Organization, along with regulators in Europe, had announced that there was no reason to suspend use of the vaccine.
According to AstraZeneca, recently, the company’s analysis of data pertaining to more than 10 million people showed “no increased risk of risk” for any age group or any batch of vaccine doses.
The company added: “In fact, the reported number of these types of cases is significantly lower among those who received the vaccine than expected.”
Regulators in Europe are looking at at least 30 cases of blood clots, out of some five million people who have taken at least one dose of the vaccine.
For her part, a spokeswoman for the World Health Organization, Margaret Harris, said on Friday that “we must continue to use the AstraZeneca vaccine, and there is no reason not to use it.”
Harris said it is “an excellent vaccine,” adding that there is no causal relationship between it and the reports of blood clots.
Last February, the World Health Organization announced its approval of the emergency use of the Oxford AstraZeneca vaccine, and the organization stated in a statement that it had given “the green light for vaccines to be released globally through the Kovacs mechanism. “.
The European Union Medicines Regulatory Authority said Thursday that European countries may continue to use the AstraZeneca vaccine, while cases of blood clots that have led some countries to suspend its use are investigated.
The European Medicines Agency said in a statement that “the position of the Agency Safety Committee is that the benefits of the vaccine are even greater than its risks and can continue to be administered while the investigation of stroke cases is carried out. “.
[ad_2]
